WILLS EYE IS HIRING – CLICK HERE TO APPLY TODAY!

Retina Clinical Trials – Dry Macular Degeneration

RETINA_Research Clinical Trials Header slide
Age Related Macular Degeneration
RETINA RESEARCH
Improving patient care now and for future generations.
Age Related Macular Degeneration

Macular Degeneration Clinical Trials

Dry Age-Related Macular Degeneration

Anti-Inflammation

Apellis OAKS
Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration.
Learn more. 

Genentech (GALLEGO)
A study assessing the safety, tolerability, and efficacy of RO7171009 in participants with geographic atrophy secondary to dry age-related macular degeneration (GALLEGO).
Learn more.

Ophthotech
Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.
Learn more.

Boehringer Ingelheim Pharmaceuticals
Safety, tolerability, and pharmacokinetics of single doses BI 425809.
Learn more.

University of Virginia TOGA
Clinical study to evaluate treatment with ORACEA® (oral doxycycline) for geographic atrophy (TOGA).
Learn more.

For more information about
Retina Clinical Trials,

call 215-928-3444

Cell Based

Astellas (AIRM)
A Phase 1b dose escalation evaluation of safety and tolerability and a Phase 2 proof of concept investigation of efficacy and safety of ASP7317 for atrophy secondary to dry age-related macular degeneration.
Learn more.

Lineage/Cellcure*
Safety and efficacy study of OpRegen for treatment of advanced dry age-related macular degeneration.
Learn more.

*pending

Genetic Screening

MedSpace (Gyroscope Therapeutics)
To evaluate the natural progression of dry age-related macular degeneration.
Learn more.

Gemini Therapeutics
A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central geographic atrophy (GA) who are carriers of high-risk genetic complement variants associated with dry age-related macular degeneration (AMD).